Compare BNZI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | APVO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 8.3M |
| IPO Year | N/A | 2023 |
| Metric | BNZI | APVO |
|---|---|---|
| Price | $3.47 | $4.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $24.00 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 21.5K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | $41.28 | N/A |
| Revenue Next Year | $0.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.50 |
| 52 Week High | $8.10 | $13.11 |
| Indicator | BNZI | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 48.14 |
| Support Level | $0.98 | $4.29 |
| Resistance Level | $3.51 | $5.66 |
| Average True Range (ATR) | 1.22 | 0.31 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 41.15 | 51.69 |
Banzai International Inc is a Software as a Service (SaaS) company operating in the marketing technology (MarTech) industry. The group provides customers with tools to help them market and sell with greater efficiency and impact. Its customers include Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, Fitch Group, and many other brands. The Company has three reportable operating segments: Banzai Operating Co, Inc., OpenReel, and Vidello. Its segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions, including video production and editing, for businesses of all sizes. Geographically, it operates in the Americas, Europe, the Middle East and Africa (EMEA), and the Asia Pacific.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.